✦ LIBER ✦

Tumor volume as prognostic factor in chemoradiation for advanced head and neck cancer

✍ Scribed by Joost L. Knegjens; Michael Hauptmann; Frank A. Pameijer; Alfons J. Balm; Frank J. Hoebers; Josien A. de Bois; Johannes H. Kaanders; Carla M. van Herpen; Cornelia G. Verhoef; Oda B. Wijers; Ruud G. Wiggenraad; Jan Buter; Coen R. Rasch

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 229 KB
Volume: 33
Category: Article
ISSN: 1043-3074
DOI: 10.1002/hed.21459

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background

Tumor volume is an important predictor of outcome in radiotherapy alone. Its significance in concomitant chemoradiation (CCRT) is much less clear. We analyzed the prognostic value of primary tumor volume for advanced head and neck squamous cell carcinoma (HNSCC) treated with CCRT.

Methods

Three hundred sixty patients treated with definitive CCRT for advanced HNSCC were selected. The pretreatment MRI or CT scan was used to calculate the primary tumor volume. Median follow‐up was 19.8 months.

Results

The average primary tumor volume was 37.0 cm^3^ (range, 2.1–182.7 cm^3^; median, 28.7 cm^3^). Multivariate analysis showed a significant effect of tumor volume on local control. The hazard ratio for a local recurrence increased by 14% per 10 cm^3^ volume increase (95% CI, 8% to 21%). There was no significant independent effect of T and N status on local control.

Conclusion

📜 SIMILAR VOLUMES

Postoperative complications after chemor

Postoperative complications after chemoradiation for advanced head and neck cancer

✍ Eva Proctor; K. Thomas Robbins; Francisco Vieira; Catherine Hanchett; Grant Somm 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

## Abstract ## Background. To compare the rate of postoperative complications of patients with advanced head and neck cancer treated with the chemoradiation protocol “RADPLAT” with that of a similar cohort of patients treated with primary surgery. ## Methods. We retrospectively analyzed 50 patie

Acceleration of hyperfractionated chemor

Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer

✍ Aaron M. Allen; Mohamed Elshaikh; Francis P. Worden; Carol R. Bradford; Theodoro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 166 KB 👁 2 views

## Abstract ## Background. Our aim was to evaluate the acceleration of a hyperfractionated, concurrent chemoradiation regimen (HxCRT) for advanced head and neck squamous cell carcinoma (HNSCC). ## Methods. Patients with unresectable HNSCC were treated based on a previously published HxCRT regime

Targeted chemoradiation for advanced hea

Targeted chemoradiation for advanced head and neck cancer: Analysis of 213 patients

✍ K. Thomas Robbins; Parves Kumar; Frank S. H. Wong; William F. Hartsell; Pamela F 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

Low-dose weekly platinum-based chemoradi

Low-dose weekly platinum-based chemoradiation for advanced head and neck cancer

✍ John M. Watkins; A. Jason Zauls; Amy H. Wahlquist; Keisuke Shirai; Elizabeth Gar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB

Objectives/Hypothesis: The optimal concurrent chemoradiotherapy regimen for definitive treatment of locoregionally advanced head and neck cancer remains to be determined. The present investigation reports toxicities, disease control, patterns of failure, and survival outcomes in a large mature cohor

Prognostic value of primary tumor volume

Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma

✍ Frank J. P. Hoebers; Frank A. Pameijer; Josien de Bois; Wilma Heemsbergen; Alfon 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 1 views

## Abstract ## Background. The purpose of this study was to evaluate the prognostic value of tumor volume in head and neck squamous cell carcinoma treated with chemoradiation. ## Methods. Forty‐six patients were treated with radiotherapy and cisplatin (6 mg/m^2^ IV x20, daily). Baseline primary

Tumor volume as a prognostic factor for

Tumor volume as a prognostic factor for sarcomatosis

✍ Malcolm M. Bilimoria; Daniel J. Holtz; Nadeem Q. Mirza; Barry W. Feig; Peter W. 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 1 views

## Abstract ## BACKGROUND The appropriate therapeutic interventions for sarcomatosis, or sarcoma characterized by intraabdominal dissemination, remain unclear. The authors performed a retrospective analysis of their recent experience with patients diagnosed with sarcomatosis to determine the overa